The FDA approved umbralisib (Ukoniq, TG Therapeutics) for adults with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti–CD20-based regimen and adults with relapsed or refractory follicular lymphoma (FL) who have received at least three prior lines of systemic therapy.
“With the approval of umbralisib, we now have a targeted, oral, once-daily option, offering a needed treatment alternative for patients,” stated Dr. Nathan Fowler, a